As artificial intelligence (AI) and digital healthcare present new paradigms in the medical field, the mental health management sector utilizing brainwave technology is gaining attention as a next-generation growth engine. With the advent of a super-aged society, the importance of early diagnosis of dementia is emerging, leading to a surge in interest in simple and accurate brain function measurement technology.

In this trend, Panaxtos Co., Ltd., a leading company in brainwave technology, is gaining global attention with the world's first portable neurofeedback system. Based in Songpa, Seoul, Panaxtos is the first company to commercialize a portable brainwave training system based on neurofeedback, called 'NeuroHarmony'. The company provides verified brain training solutions in various mental health areas such as Attention Deficit Hyperactivity Disorder (ADHD), depression, insomnia, and stress improvement. Through the brain cognitive training brand 'Brint', it is leading digital health innovation that transcends the boundaries of medical care, healthcare, and education.

NeuroHarmony is a two-channel brainwave measuring device using dry electrodes, capable of accurately and safely measuring and analyzing brainwaves of the left and right brains. It provides personalized brain training solutions by quantifying the user's concentration, stress, and emotional state through NeuroSpec, BQ, and BQM tests.

Panaxtos's technology has recently been recognized internationally. Through joint research with the research team at the International St. Mary's Hospital of Catholic Kwandong University, it announced research results that can distinguish Alzheimer's-type dementia patients with high accuracy using wearable brainwave devices and AI models. This research was published in April in the international academic journal 'Scientific Reports', under the Nature Portfolio. The research team measured brainwaves using the wearable brainwave device NeuroHarmony, which is simply attached to the forehead, on 29 Alzheimer's patients and 54 normal control subjects. The application of the AI analysis model allowed them to distinguish dementia patients from the control group with a balanced accuracy of 97.05% using just one specific brainwave indicator.

Contributing to the Popularization and Specialization of Brain Science Education

CEO Park Byung-woon, a physicist who obtained his Ph.D. in the United States, established the Korea Institute of Mental Science in 1996 after returning home and working at the Electronics and Telecommunications Research Institute. He later founded Changse Co., the predecessor of Panaxtos, and launched the revolutionary two-player brainwave game console 'Q-jump', which caused a significant stir. In 2002, the company changed its name to BrainTech and developed a portable neurofeedback system, establishing its position as a leading brainwave company in Korea.

CEO Park stated, "Unlike Elon Musk, who implants chips in the brain to mechanize humans, we focus on developing human innate abilities through brainwave analysis," and added, "As a company pursuing humanitarian values in the AI era, we will concentrate on technology development encompassing brain diagnosis, treatment, and development."

Panaxtos is committed not only to technology development but also to realizing social value. It supports the NeuroHarmony system for 11 juvenile detention centers, educational institutions, and welfare blind spots nationwide, contributing to emotional recovery and learning ability improvement. It has been operating private qualification courses for 'brain educators' and 'brain counselors', producing over 10,000 experts since 2003. The company has signed MOUs with educational institutions such as Talent University, Dong-Eui University, and Ewha Womans University, contributing to the popularization and specialization of brain science education.

Currently, Panaxtos headquarters is running a free trial program for NeuroHarmony. It offers trial opportunities to children and adolescents experiencing memory, concentration, emotional fluctuation, and sleep disorders, as well as those over 60 years old. Panaxtos has already obtained FDA registration in the United States, domestic medical device certification, and KC certification. It has established centers in the United States, Canada, Australia, Southeast Asia, and China, laying the foundation for exporting 'K-Brain Health' technology. This month, it signed an investment consulting contract worth approximately USD 25 million (about KRW 35 billion) to enter the U.S. market.

CEO Park stated, "We are receiving a hotter response overseas, and significant achievements are expected in the global market in the future," and added, "We plan to promote multi-center clinical research and the commercialization of dementia-related solutions based on brainwaves." The future of Panaxtos, which is presenting a new medical paradigm through the convergence of brain science and AI technology, and realizing the enhancement of human brain function and mental health improvement, is anticipated.

Popular News